A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL)

Background: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway integrates signals from multiple receptor tyrosine kinases to control cell proliferation and survival. Everolimus (RAD001, Novartis Pharmaceuticals) is an oral investigational antineoplasti...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2007-11, Vol.110 (11), p.121-121
Main Authors: Reeder, Craig B., Gornet, Michel K., Habermann, Thomas M., Ansell, Stephen M., Micallef, Ivana N., Porrata, Luis F., Johnston, Patrick B., Maurer, Matthew J., LaPlant, Betsy, Kabat, Brian, Inwards, David J., Colgan, Joseph P., Call, Timothy, Markovic, Svetomir, Zent, Clive S., Zeldenrust, Steven R., Tun, Han W., Witzig, Thomas E.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway integrates signals from multiple receptor tyrosine kinases to control cell proliferation and survival. Everolimus (RAD001, Novartis Pharmaceuticals) is an oral investigational antineoplastic agent that targets mTOR. Objectives: To learn the anti-tumor activity and toxicity of single-agent RAD001 in pts with relapsed/refractory aggressive NHL. Patients and Methods: Patients were eligible if they had measurable disease, a platelet count >75,000, an absolute neutrophil count >1,000, and a creatinine and bilirubin
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V110.11.121.121